Dresbuxelimab is under clinical development by Akeso and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC). According to GlobalData, Phase I drugs for Head And Neck Squamous Cell Carcinoma (HNSC) have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Dresbuxelimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dresbuxelimab (AK-119) is under development for the treatment of advanced or metastatic solid tumor, metastatic colorectal cancer, pancreatic ductal adenocarcinoma, non-small cell lung cancer, kidney cancer (renal cell cancer), head and neck cancer squamous cell carcinoma, triple-negative breast cancer (TNBC), castration-resistant prostate cancer (CRPC), ovarian cancer, idiopathic pulmonary fibrosis, coronavirus disease 2019 (COVID-19). The drug candidates act by targeting CD73. It is administered intravenously.
Akeso is a clinical-stage biopharmaceutical company that focuses on in-house discovery and development of mono and bi-specific antibody drugs. The company’s product pipeline includes Ak101 and Ak111 targeting plaque psoriasis; Ak102 for the treatment of hypercholesterolemia; Ak104 against cancer; Ak105 for treating anlotinib; and Ak112 against solid tumors. It also offers kangfang integrated development platform (ACE Platform) which covers all drug R & D, including target verification, antibody discovery and also development functions. The company works in partnership with MERCK & CO Inc, Dawnrays Pharmaceutical Holdings Ltd, Sino Biopharmaceutical Ltd and China Biopharma. Akeso is headquartered in Zhongshan, Guangdong, China
For a complete picture of Dresbuxelimab’s drug-specific PTSR and LoA scores, buy the report here.